Lumida
/IKT
⌘K
Inhibikase Therapeutics Inc

Inhibikase Therapeutics Inc

IKT
$2.34USD+0.43%+0.01 today

MARKET CAP

326.5M

P/E (TTM)

FWD P/E

DAY RANGE

$2 – $2

52W RANGE

$1
$3
STATEMENT·Income statement
USD · GAAP
METRICFY 2020FY 2021FY 2022FY 2023TREND
Sales, Adj.$698,468$3.1M$123,440$260,501
YoY %+343.9%-96.0%+111.0%
P / Sales81.1x8.6x111.3x30.8x
EV / Sales68.3x-3.2x84.7x9.2x
Gross Profit, Adj.$698,468$3.1M$123,440$260,501
YoY %+343.9%-96.0%+111.0%
Margin %100.0%100.0%100.0%100.0%
EV / Gross Profit68.3x-3.2x84.7x9.2x
EBITDA, Adj.$-2.8M$-14.8M$-18.1M$-19.9M
YoY %-423.9%-22.7%-9.9%
Margin %-403.5%-476.2%-14680.7%-7643.9%
EV / EBITDA-16.9x0.7x-0.6x-0.1x
EBIT$-2.8M$-14.8M$-18.1M$-20.1M
YoY %-423.9%-22.8%-10.8%
Margin %-403.5%-476.2%-14686.2%-7712.0%
EV / EBIT-16.9x0.7x-0.6x-0.1x
Net Income$-2.8M$-14.8M$-18.1M$-19.0M
YoY %-419.2%-22.1%-5.4%
Net Margin-407.7%-476.9%-14625.9%-7304.7%
EPS (GAAP)-$2.10-$4.86-$4.28-$3.16
YoY %-131.4%+11.9%+26.2%